Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05100095 · ClinicalTrials.gov registry record · Phase 2
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
A Phase 2 study of Merkel Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT05100095 is a Phase 2 study of Merkel Cell Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 52 participants, roughly in line with the 49-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT05100095, a Phase 2 study of Merkel Cell Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests whether hypofractionated radiation works to treat patients with Merkel cell carcinoma. Radiation therapy uses high energy radio waves to kill cancer cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may be more convenient for patients and less immunosuppressive.
Conditions Studied
Interventions
- DRUG Radiation therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05100095
The ClinicalTrials.gov registry entry for NCT05100095 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 49-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Merkel Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Radiation therapy is the first listed.
NCT05100095 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05100095 about?
NCT05100095 is a clinical study titled "Hypofractionated Radiation Therapy for Merkel Cell Carcinoma". This phase II trial tests whether hypofractionated radiation works to treat patients with Merkel cell carcinoma. Radiation therapy uses high energy radio waves to kill cancer cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period ...
What is the current status of trial NCT05100095?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2021-12-14. Estimated completion is 2028-09-01.
What conditions does trial NCT05100095 study?
This clinical trial studies the following conditions: Merkel Cell Carcinoma.
What interventions are being tested in trial NCT05100095?
The interventions under investigation include: Radiation therapy (DRUG).
Who is sponsoring clinical trial NCT05100095?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05100095 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Merkel Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.